Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14965239 | 0.90 | GPR55 (0.42) | GPR55OPRK1MEN1KMT2ATP53 | |
| SCHEMBL14965464 | 0.79 | TP53 (0.41) | GPR55MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14965298 | 0.78 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL14964931 | 0.77 | GPR55 (0.45) | GPR55MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL14965367 | 0.77 | SMN1; SMN2 (0.44) | GPR55MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16293147 | 0.75 | LMNA (0.51) | MEN1KMT2ASMN1; SMN2HPGDLMNA | |
| SCHEMBL14965141 | 0.75 | GPR55 (0.43) | GPR55MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14965004 | 0.74 | MEN1 (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL14965159 | 0.74 | TP53 (0.37) | TP53RXFP1 | |
| SCHEMBL14965198 | 0.73 | TP53 (0.37) | TP53RXFP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | GPR55 1175/4885OPRK1 1173/4885BCAT2 2738/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | GPR55 1144/4885OPRK1 1141/4885BCAT2 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.